Clin Osteol 2018; 23(4): 176-180

Clinical perspective of RANK/RANKL/OPG system components in rheumatoid arthritisReview articles

Gažová Andrea1, Kužma Martin2, Killinger Zdenko2, Payer Juraj2, Kyselovič Ján2
1 Ústav farmakológie a klinickej farmakológie, LF UK, Bratislava, Slovensko
2 V. interná klinika, LF UK a UNB, Nemocnica Ružinov, Bratislava, Slovensko

Rheumatoid arthritis (RA) is a chronic, systemic, inflammatory autoimmune disease affecting mainly synovial tissue as its primary target. Uncontrolled disease activity causes not only joint destruction but is associated with increased mortality mainly due to cardiovascular involvement. Understanding the role of cytokines in patophysiology of RA and their link to cardiovascular system could contribute to cardiovascular risk markers detection in RA patients.

Keywords: cardiovascular system; NF-κB signal system; RANK, RANKL, OPG; rheumatoid arthritis

Received: November 14, 2018; Accepted: December 3, 2018; Published: December 11, 2018  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Gažová A, Kužma M, Killinger Z, Payer J, Kyselovič J. Clinical perspective of RANK/RANKL/OPG system components in rheumatoid arthritis. Clinical Osteology. 2018;23(4):176-180.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Rochette L, Meloux A, Rigal E et al. The role of osteoprotegerin in the crosstalk between vessels and bone: Its potential utility as a marker of cardiometabolic diseases. Pharmacol Ther 2018;182 : 115-132. Dostupné z DOI: <http://doi:10.1016/j.pharmthera.2017.08.015>. Go to original source...
    2. Masoud S, Lim PB, Kitas GD et al. Sudden cardiac death in patients with rheumatoid arthritis. World J Cardiol 2017; 9(7): 562-573. Dostupné z DOI: <http://doi:10.4330/wjc.v9.i7.562>. Go to original source...
    3. Abraham C, Cho JH. Inflammatory bowel disease. N Engl J Med 2009; 361(21): 2066-2078. Dostupné z DOI: <http://doi:10.1056/NEJMra0804647>. Go to original source...
    4. Wallace KL, Zheng LB, Kanazawa Y et al. Immunopathology of inflammatory bowel disease. World J Gastroenterol 2014; 20(1): 6-21. Dostupné z DOI: <http://doi:10.3748/wjg.v20.i1.6>. Go to original source...
    5. McInnes IB, Schett G. The pathogenesis of rheumatoid arthritis. N Engl J Med 2011; 365(23): 2205-2219. Dostupné z DOI: <http://doi:10.1056/NEJMra1004965>. Go to original source...
    6. Liu T, Zhang L, Joo D et al. NF-κB signaling in inflammation. Signal Transduct Targeted Ther 2017; 2: e17023. Dostupné z DOI: <http://doi:10.1038/sigtrans.2017.23 >. Go to original source...
    7. Noort AR, Tak PP, Tas SW. Non-canonical NF-κB signaling in rheumatoid arthritis: Dr Jekyll and Mr Hyde? Arthritis Res Ther 2015;17(1):15. Dostupné z DOI: <http://doi:10.1186/s13075-015-0527-3>. Go to original source...
    8. Sun SC. Non-canonical NF-kappaB signaling pathway. Cell Res 2011; 21 : 71-85. Dostupné z DOI: <http://doi:10.1038/cr.2010.177>. Go to original source...
    9. Beinke S, Ley SC. Functions of NF-kappaB1 and NF-kappaB2 in immune cell biology. Biochem J 2004; 382(Pt 2): 393-409. Dostupné z DOI: <http://doi:10.1042/BJ20040544>. Go to original source...
    10. Vallabhapurapu S, Karin M. Regulation and function of NF-kappaB transcription factors in the immune system. Annu Rev Immunol 2009; 27 : 693-733. Dostupné z DOI: <http://doi:10.1146/annurev.immunol.021908.132641>. Go to original source...
    11. Zhang H, Sun SC. NF-kappaB in inflammation and renal diseases. Cell Biosci 2015; 5 : 63. Dostupné z DOI: <http://doi:10.1186/s13578-015-0056-4>. Go to original source...
    12. Karin M, Delhase M. The I kappa B kinase (IKK) and NF-kappa B: key elements of proinflammatory signalling. Semin Immunol 2000; 12(1): 85-98. Dostupné z DOI: <http://doi:10.1006/smim.2000.0210>. Go to original source...
    13. Sun SC, Ley SC. New insights into NF-kappaB regulation and function. Trends Immunol 2008; 29(10): 469-478.. Dostupné z DOI: <http://doi:10.1016/j.it.2008.07.003>. Go to original source...
    14. Israel A. The IKK complex, a central regulator of NF-kappaB activation. Cold Spring Harb Perspect Biol 2010; 2(3):a000158. Dostupné z DOI: <http://doi:10.1101/cshperspect.a000158>. Go to original source...
    15. Wei F, Chang Y, Wei W. The role of BAFF in the progression of rheumatoid arthritis. Cytokine 2015; 76(2): 537-544. Dostupné z DOI: <http://doi:10.1016/j.cyto.2015.07.014>. Go to original source...
    16. Tas SW, Remans PH, Reedquist KA et al. Signal transduction pathways and transcription factors as therapeutic targets in inflammatory disease: towards innovative antirheumatic therapy. Curr Pharm Des 2005; 11(5): 581-611. Go to original source...
    17. Tak PP, Firestein GS. NF-kappaB: a key role in inflammatory diseases. J Clin Invest 2001;107(1): 7-11. Dostupné z DOI: <http://doi:10.1172/JCI11830>. Go to original source...
    18. Weih F, Carrasco D, Durham SK et al. Multiorgan inflammation and hematopoietic abnormalities in mice with a targeted disruption of RelB, a member of the NF-kappa B/Rel family. Cell 1995; 80(2): 331-340. Go to original source...
    19. Aya K, Alhawagri M, Hagen-Stapleton A et al. NF-(kappa)B-inducing kinase controls lymphocyte and osteoclast activities in inflammatory arthritis. J Clin Invest 2005; 115(7): 1848-1854. Dostupné z DOI: <http://doi:10.1172/JCI23763>. Go to original source...
    20. Bresnihan B, Pontifex E, Thurlings RM et al. Synovial tissue sublining CD68 expression is a biomarker of therapeutic response in rheumatoid arthritis clinical trials: consistency across centers. J Rheumatol 2009; 36(8): 1800-1802. Dostupné z DOI: <http://doi:10.3899/jrheum.090348>. Go to original source...
    21. Firestein GS. Evolving concepts of rheumatoid arthritis. Nature 2003; 423(6937): 356-361. Dostupné z DOI: <http://doi:10.1038/nature01661>. Go to original source...
    22. Rochette L, Meloux A, Rigal E et al. The role of osteoprotegerin in the crosstalk between vessels and bone: Its potential utility as a marker of cardiometabolic diseases. Pharmacol Ther 2018; 82 : 115-132. Dostupné z DOI: <http://doi:10.1016/j.pharmthera.2017.08.015>. Go to original source...
    23. Kiechl S, Werner P, Knoflach M et al. The osteoprotegerin/RANK/RANKL system: A bone key to vascular disease. Expert Rev Cardiovasc Ther 2006; 4(6): 801-811. Dostupné z DOI: <http://doi:10.1586/14779072.4.6.801>. Go to original source...
    24. Jono S, Otsuki S, Higashikuni Y et al. Serum osteoprotegerin levels and long-term prognosis in subjects with stable coronary artery disease. J Thromb Haemost 2010; 8(6): 1170-1175. Dostupné z DOI: <http://doi:10.1111/j.1538-7836.2010.03833.x>. Go to original source...

    Return to the content


    Clinical Osteology

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.